Kezar Life Sciences Inc.宣布，美国食品药品监督管理局（FDA）已解除对其PORTOLA 2a期试验的部分临床保留。这项试验旨在评估首创选择性免疫蛋白酶体抑制剂zetomipzomib用于治疗自身免疫性肝炎（AIH）的疗效与安全性。FDA的决定基于对zetomipzomib项目全面的安全性评估结果。
公司首席执行官Chris Kirk表达了对该药物潜力的乐观预期，认为其可能为AIH患者带来积极影响。他同时透露，将就后续临床试验设计与FDA展开深入讨论。尽管狼疮肾炎（LN）领域的开发已暂停，以集中资源于AIH适应症，但Kezar计划依据独立数据监测委员会的建议，寻求解除zetomipzomib在LN领域的临床保留。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.